In the post-hoc analysis, the findings indicated that PD-1 inhibitors had a significantly higher risk of pancreatic AEs compared to PD-L1 inhibitors, consistent with other immune-related adverse events, such as pneumonitis (15). This evidence concerns the gene PDCD1 and pneumonitis.